WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412395

CAS#: 89213-87-6

Description: Carperitide is a biochemical used in the treatment of Decompensated Congestive Heart Failure

Chemical Structure

CAS# 89213-87-6

Theoretical Analysis

MedKoo Cat#: 412395
Name: Carperitide
CAS#: 89213-87-6
Chemical Formula: C127H203N45O39S3
Exact Mass: 3078.4447
Molecular Weight: 3080.48
Elemental Analysis: C, 49.52; H, 6.64; N, 20.46; O, 20.26; S, 3.12

Price and Availability

Size Price Availability Quantity
1.0mg USD 495.0 2 Weeks
Bulk inquiry

Synonym: Carperitide; SUN4936; SUN-4936; SUN 4936

IUPAC/Chemical Name: ((4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-amino-3-hydroxypropanamido)-4-methylpentanamido)-5-guanidinopentanamido)-5-guanidinopentanamido)-3-hydroxypropanamido)-3-hydroxypropanamido)-19-(3-amino-3-oxopropyl)-49-benzyl-28-((S)-sec-butyl)-34-(carboxymethyl)-31,40-bis(3-guanidinopropyl)-16-(hydroxymethyl)-10-isobutyl-22-methyl-37-(2-(methylthio)ethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane-4-carbonyl)-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-L-tyrosine


InChi Code: InChI=1S/C127H203N45O39S3/c1-9-64(6)99-121(209)150-52-94(182)151-65(7)100(188)155-76(34-35-91(129)179)109(197)167-85(56-174)104(192)149-53-96(184)153-78(43-62(2)3)102(190)148-54-97(185)154-89(119(207)164-82(48-92(130)180)114(202)169-86(57-175)116(204)163-81(46-67-23-14-11-15-24-67)113(201)158-73(27-18-39-143-125(135)136)107(195)166-84(122(210)211)47-68-30-32-69(178)33-31-68)60-213-214-61-90(171-118(206)88(59-177)170-117(205)87(58-176)168-108(196)74(28-19-40-144-126(137)138)156-106(194)72(26-17-38-142-124(133)134)157-112(200)79(44-63(4)5)161-101(189)70(128)55-173)120(208)162-80(45-66-21-12-10-13-22-66)103(191)147-50-93(181)146-51-95(183)152-71(25-16-37-141-123(131)132)105(193)160-77(36-42-212-8)110(198)165-83(49-98(186)187)115(203)159-75(111(199)172-99)29-20-41-145-127(139)140/h10-15,21-24,30-33,62-65,70-90,99,173-178H,9,16-20,25-29,34-61,128H2,1-8H3,(H2,129,179)(H2,130,180)(H,146,181)(H,147,191)(H,148,190)(H,149,192)(H,150,209)(H,151,182)(H,152,183)(H,153,184)(H,154,185)(H,155,188)(H,156,194)(H,157,200)(H,158,201)(H,159,203)(H,160,193)(H,161,189)(H,162,208)(H,163,204)(H,164,207)(H,165,198)(H,166,195)(H,167,197)(H,168,196)(H,169,202)(H,170,205)(H,171,206)(H,172,199)(H,186,187)(H,210,211)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)(H4,139,140,145)/t64-,65-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,99-/m0/s1

SMILES Code: CC[C@@H]([C@@H]1NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CO)N)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CO)=O)CO)=O)CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)Cc2ccc(O)cc2)=O)CCCNC(N)=N)=O)Cc3ccccc3)=O)CO)=O)CC(N)=O)=O)NC(CNC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC(CNC1=O)=O)C)=O)CCC(N)=O)=O)CO)=O)=O)CC(C)C)=O)=O)=O)Cc4ccccc4)=O)=O)=O)CCCNC(N)=N)=O)CCSC)=O)CC(O)=O)=O)CCCNC(N)=N)=O)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 3080.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Kawase Y, Hata R, Tada T, Katoh H, Kadota K. Effects of Carperitide on Degree of Pulmonary Congestion in Treatment of Acute Heart Failure. Circ J. 2018 Jul 25;82(8):2079-2088. doi: 10.1253/circj.CJ-18-0057. Epub 2018 May 24. PMID: 29794402.

2: Nagai T, Iwakami N, Nakai M, Nishimura K, Sumita Y, Mizuno A, Tsutsui H, Ogawa H, Anzai T; JROAD-DPC investigators. Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure: Insight from a nationwide claim- based database. Int J Cardiol. 2019 Apr 1;280:104-109. doi: 10.1016/j.ijcard.2019.01.049. Epub 2019 Jan 15. PMID: 30674432.

3: Kamiya M, Sato N, Matsuda J, Nozaki A, Akiya M, Sato T, Okazaki H, Takahashi Y, Shimizu W. Predictors of responders for low-dose carperitide monotherapy in patients with acute heart failure. Heart Vessels. 2020 Jan;35(1):59-68. doi: 10.1007/s00380-019-01450-w. Epub 2019 Jun 21. PMID: 31227874.

4: Sezai A, Osaka S, Yaoita H, Ishii Y, Arimoto M, Hata H, Shiono M. Efficacy of Carperitide in Hemodialysis Patients Undergoing Cardiac Surgery. Ann Thorac Cardiovasc Surg. 2016 Aug 23;22(4):237-45. doi: 10.5761/atcs.oa.15-00239. Epub 2016 Mar 30. PMID: 27025780; PMCID: PMC5045851.

5: Mizuno A, Iguchi H, Sawada Y, Hurley M, Nomura H, Hayashi K, Tokuda Y, Watanabe S, Yoshikawa A. The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure: High value care vs. low value care campaign in Japan. Int J Cardiol. 2017 Aug 15;241:243-248. doi: 10.1016/j.ijcard.2017.04.078. Epub 2017 Apr 26. PMID: 28476514.

6: Ogiso M, Isogai T, Okabe Y, Ito K, Tsuji M, Tanaka H. Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses. Heart Vessels. 2017 Aug;32(8):916-925. doi: 10.1007/s00380-017-0952-0. Epub 2017 Feb 20. PMID: 28220240.

7: Sasabuchi Y, Yasunaga H, Matsui H, Lefor AK, Fushimi K, Sanui M. Carperitide Increases the Need for Renal Replacement Therapy After Cardiovascular Surgery. J Cardiothorac Vasc Anesth. 2015 Dec;29(6):1426-31. doi: 10.1053/j.jvca.2015.04.022. Epub 2015 Apr 28. PMID: 26275514.

8: Tsukamoto M, Koyama S, Esaki K, Hitosugi T, Yokoyama T. Low-dose carperitide (α-human A-type natriuretic peptide) alleviates hemoglobin concentration decrease during prolonged oral surgery: a randomized controlled study. J Anesth. 2017 Jun;31(3):325-329. doi: 10.1007/s00540-017-2309-3. Epub 2017 Jan 30. PMID: 28138765.

9: Matsue Y, Kagiyama N, Yoshida K, Kume T, Okura H, Suzuki M, Matsumura A, Yoshida K, Hashimoto Y. Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis. J Card Fail. 2015 Nov;21(11):859-64. doi: 10.1016/j.cardfail.2015.05.007. Epub 2015 May 18. PMID: 25999241.

10: Nagai T, Honda Y, Nakano H, Honda S, Iwakami N, Mizuno A, Komiyama N, Yamane T, Furukawa Y, Miyagi T, Nishihara S, Tanaka N, Adachi T, Hamasaki T, Asaumi Y, Tahara Y, Aiba T, Sugano Y, Kanzaki H, Noguchi T, Kusano K, Yasuda S, Ogawa H, Anzai T. Rationale and Design of Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF). Cardiovasc Drugs Ther. 2017 Dec;31(5-6):551-557. doi: 10.1007/s10557-017-6760-z. PMID: 29098501.